In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Sarepta nets $477.5mm via FOPO

12 Nov 2018

Executive Summary

Rare disease-focused Sarepta Therapeutics Inc. netted $477.5mm through the follow-on public offering of 3.8mm common shares at $131 each. The company will use the proceeds for R&D and manufacturing activities and to finance capital expenditures and capacity expansions.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Antisense, Oligonucleotides
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By